

# Long-Term Symptoms among COVID-19 Survivors in Prospective Cohort Study, Brazil

Lívia P. Bonifácio, Viviane N.F. Csizmar, Francisco Barbosa-Júnior, Ana P.S. Pereira, Marcel Koenigkam-Santos, Danilo T. Wada, Gilberto G. Gaspar, Felipe S. Carvalho, Valdes R. Bollela, Rodrigo C. Santana, João P. Souza, Fernando Bellissimo-Rodrigues

We conducted a prospective cohort study in a population with diverse ethnic backgrounds from Brazil to assess clinically meaningful symptoms after surviving coronavirus disease. For most of the 175 patients in the study, clinically meaningful symptoms, including fatigue, dyspnea, cough, headache, and muscle weakness, persisted for  $\geq 120$  days after disease onset.

Understanding is growing that coronavirus disease (COVID-19) can evolve and continue to cause prolonged symptoms, characterizing the post-COVID-19 condition (1–3). Potential implications go beyond effects on individual patients and might represent an additional burden on healthcare services and social security, which are both already affected by the pandemic. Therefore, learning more about the long-term repercussions of the disease among different populations is essential. This study aimed to describe the occurrence of long-term physical, psychological, and social consequences among patients who survived COVID-19 and received follow-up care at a post-COVID-19 outpatient clinic at a university hospital in Brazil.

## The Study

This prospective cohort study (RECOVIDA) was performed among patients attending a post-

COVID-19 outpatient clinic at Ribeirão Preto Medical School University Hospital, Ribeirão Preto, Brazil (4). The institutional review board approved the research protocol.

All adults with PCR-confirmed COVID-19 with symptom onset during February 1–December 31, 2020, who attended follow-up appointments at the study clinic were eligible. Most participants (85.7%) had been discharged after being hospitalized for COVID-19. The remaining participants (14.3%) were mostly health-care workers from the study facility. No participants had been previously vaccinated against COVID-19. Patients were classified into 3 groups according to the World Health Organization (WHO) severity classification of COVID-19: mild/moderate, severe, and critical (5) (Appendix Table 1, <https://wwwnc.cdc.gov/EID/article/28/3/21-2020-App1.pdf>).

This study was exploratory, and sample size was established through convenience. We aimed to include all patients who attended the clinic during the study period and agreed to participate.

Participants were recruited just before the scheduled medical consultation. After the informed consent form was signed, we performed a structured interview and a brief physical examination. We obtained secondary data from patients' electronic health records. Laboratory and imaging tests were performed at the attending physician's clinical discretion. We collected study data by using the Research Electronic Data Capture platform (6).

We collected information on economic and demographic social profile, medical history, date of symptom onset, hospitalization data, laboratory and imaging test results, persistent symptoms, and quality of life. We assessed quality of life by using the WHO Quality of Life questionnaire (7–9) (Appendix). The date of symptom onset was used as the reference for follow-up.

Author affiliations: Ribeirão Preto Medical School Social Medicine Department, University of São Paulo, São Paulo, Brazil (L.P. Bonifácio, V.N.F. Csizmar, F. Barbosa-Júnior, A.P.S. Pereira, J.P. Souza, F. Bellissimo-Rodrigues); Ribeirão Preto Medical School Department of Medical Images, Hematology and Clinical Oncology, University of São Paulo, Ribeirão Preto, Brazil (M. Koenigkam-Santos, D.T. Wada); Ribeirão Preto Medical School Infectious and Tropical Diseases Division of Internal Medicine Department, University of São Paulo, Ribeirão Preto (G.G. Gaspar, F.S. Carvalho, V.R. Bollela, R.C. Santana)

DOI: <https://doi.org/10.3201/eid2803.212020>

We performed statistical procedures by using Minitab 19.2 (<https://www.minitab.com>) and Stata version 9 (<https://www.stata.com>). We used odds ratios, 95% CIs, and Fisher exact tests to verify the association between the persistence of symptoms and the severity of disease.

During the study period, 297 patients had a follow-up medical consultation scheduled at the outpatient clinic. We included 175 patients in this study (Table 1; Figure). In this sample, 20% of participants had illness that was considered mild/moderate, 45.7% were severe, and 34.3% were critical.

After COVID-19, 80% of the patients experienced persistent symptoms; the 5 most prevalent were fatigue, dyspnea, cough, headache, and loss of overall muscle strength. Compared with the mild/moderate group, patients from the critical group more frequently experienced headaches, change in skin sensitivity, hypogeusia, hyposmia, and loss of muscle strength (Table 2, <https://wwwnc.cdc.gov/EID/article/28/3/21-2020-T2.htm>).

Regarding quality of life after COVID-19, physical health was more severely affected than the other 3 domains evaluated by the WHO Quality of Life questionnaire (psychological, social relationships, and environmental). Moreover, the comparative evaluation before and after COVID-19 showed a decrease from 81.1% to 68.4% in the percentage of patients who believed that their quality of life was good or very good and an increase from 2.3% to 6.4% of those who believed that their quality of life was poor or very poor. Despite these changes, more than half of patients (56.7%) were satisfied with their current health status at the time of evaluation (Appendix).

**Table 1.** Baseline clinical and demographic characteristics among 175 patients surviving the acute phase of COVID-19, Ribeirão Preto, Brazil\*

| Characteristic                           | COVID-19 severity           |                        |                          | Total, n = 175   |
|--|-----------------------------|------------------------|--------------------------|------------------|
|  | Mild/moderate, n = 35 (20%) | Severe, n = 80 (45.7%) | Critical, n = 60 (34.3%) |                  |
| Sex                                      |                             |                        |                          |                  |
| M  | 7 (20)                      | 36 (45)                | 42 (70)                  | 85 (48.6)        |
| F  | 28 (80)                     | 44 (55)                | 18 (30)                  | 90 (51.4)        |
| Mean age, y (SD)                         | 44.9 (+10.3)                | 57.1 (+15.3)           | 54.2 (+13.2)             | 53.7 (+14.4)     |
| Ethnic background†                       |                             |                        |                          |                  |
| White (Caucasian or Latin)               | 19 (54.3)                   | 36 (45)                | 25 (41.7)                | 80 (45.7)        |
| Afro-American (Brown)                    | 10 (28.6)                   | 34 (42.5)              | 26 (43.3)                | 70 (40)          |
| Afro-American (Black)                    | 6 (17.1)                    | 8 (10)                 | 6 (10)                   | 20 (11.4)        |
| Asiatic                                  | 0                           | 1 (1.3)                | 2 (3.3)                  | 3 (1.7)          |
| Brazilian Indigenous                     | 0                           | 1 (1.3)                | 1 (1.7)                  | 2 (1.1)          |
| Mean years of schooling (SD)             | 13.4 (+5.7)                 | 8.1 (+5.5)             | 8.3 (+5.4)               | 9.2 (+5.9)       |
| Mean income/person, USD (SD)‡            | 407.33 (+313.60)            | 273.01 (+295.85)       | 229.33 (+210.40)         | 285.57 (+279.56) |
| Median                                   | 364.01                      | 200.21‡                | 182.01‡                  | 216.77‡          |
| Currently works as a health professional |                             |                        |                          |                  |
| Yes                                      | 23 (65.7)                   | 8 (10)                 | 2 (3.3)                  | 33 (18.9)        |
| No                                       | 12 (34.3)                   | 72 (90)                | 58 (96.7)                | 142 (81.1)       |
| Mean BMI (SD)§                           | 31.8 (+7.5)                 | 32.1 (+7.3)§           | 31.1 (+7.5)              | 31.7 (+7.3)§     |
| BMI ≥30§                                 | 17 (48.6)                   | 44 (56.4)§             | 23 (38.3)                | 84 (48.6)§       |
| Underlying conditions                    |                             |                        |                          |                  |
| None                                     | 16 (45.7)                   | 16 (20)                | 10 (16.7)                | 42 (24.0)        |
| Hypertension                             | 9 (25.7)                    | 35 (43.8)              | 21 (35)                  | 65 (37.1)        |
| Diabetes                                 | 1 (2.9)                     | 26 (32.5)              | 22 (36.7)                | 49 (28.0)        |
| Dyslipidemia                             | 2 (5.7)                     | 12 (15)                | 12 (20)                  | 26 (14.8)        |
| Heart problems (other than hypertension) | 1 (2.9)                     | 10 (12.5)              | 8 (13.3)                 | 19 (10.9)        |
| Rhinitis or sinusitis                    | 3 (8.6)                     | 7 (8.8)                | 7 (11.7)                 | 17 (9.7)         |
| Cancer                                   | 1 (2.9)                     | 9 (11.3)               | 1 (1.7)                  | 11 (6.3)         |
| Thyroid problems                         | 0                           | 4 (5)                  | 6 (10)                   | 10 (5.7)         |
| Depression or anxiety                    | 1 (2.9)                     | 6 (7.5)                | 3 (5)                    | 10 (5.7)         |
| Smoking                                  |                             |                        |                          |                  |
| Current                                  | 0 (0)                       | 2 (2.5)                | 0                        | 2 (1.1)          |
| Previous                                 | 2 (5.71)                    | 18 (22.5)              | 19 (31.7)                | 39 (22.3)        |
| Hospitalization                          |                             |                        |                          |                  |
| Yes                                      | 10 (28.6)                   | 80 (100)               | 60 (100)                 | 150 (85.7)       |
| No                                       | 25 (71.4)                   | 0                      | 0                        | 25 (14.3)        |
| Mean duration of hospitalization, d (SD) | 5 (+4)                      | 9.9 (+5.2)             | 24.1 (+11.1)             | 15.3 (+10.9)     |
| Median                                   | 4                           | 9                      | 20.5                     | 12               |

\*Values are no. (%) except as indicated. BMI, body mass index; COVID-19, coronavirus disease.

†Ethnic background information was self-reported and consisted of Latin American, Caucasian, Afro-American, Asian, and Brazilian indigenous persons.

‡\$1 US = R \$5.49. Data on financial income by person were missing for 3 participants.

§BMI data were missing for 2 participants.

## Conclusions

We describe the long-term repercussions of COVID-19 among a sample of patients in Brazil from diverse social and ethnic backgrounds who survived acute infection and attended a follow-up ambulatory clinic appointment. We identified that most patients experienced  $\geq 1$  symptom for  $\geq 120$  days after the onset of disease. This finding also applies to patients who had a mild or moderate form of COVID-19. These symptoms negatively affected the patients' quality of life; fatigue was the most common symptom, followed by dyspnea and cough.

The clinical picture we describe here, in a population with a mixed ethnic background consisting

of Latin American, Caucasian, Afro-American, Asian, and Brazilian indigenous persons, is similar to those encountered in other parts of the world, mainly in Caucasian or Asian populations (1,10–12). Some persistent symptoms found in our study, such as altered skin sensitivity and muscle weakness, primarily affected the patients whose illness was critical, and this finding could be more related to their stay in the intensive care unit than to the COVID-19 itself (13).


Several possible pathophysiological explanations for the persistence of symptoms after COVID-19 have been proposed. The most commonly elicited in the literature are direct viral toxicity, endothelial damage, dysregulated immune response, hyperinflammation, hypercoagulability, and poor adaptation of the angiotensin-converting enzyme 2. So far, the actual mechanisms behind this scenario are not entirely understood and deserve further evaluation (1,10–13). Our sample identified that respiratory and heart rates were significantly higher in the patients whose illness was critical, possibly indicating impairment of autonomic function in these patients (14,15).

We highlight the need to study the persistent symptoms of patients with COVID-19, given the implications for the healthcare system and social security, both of which are already profoundly affected by the pandemic itself. From this perspective, most persons with COVID-19 requiring medical consultation would not be expected to recover fully or resume working immediately after the end of the disease's acute phase. Instead, they will require a prolonged interdisciplinary healthcare approach focused on physical, mental, and social rehabilitation (1,10–15).

We did not perform genetic sequencing of the severe acute respiratory syndrome coronavirus 2 detected in our patients. Therefore, we cannot evaluate whether different virus variants might affect the occurrence of long-term symptoms among survivors differently.

One of the strengths of our study was our systematic follow-up on participants with prespecified instruments, which ensured high-quality and consistent data. A novelty of the study was that we were able to recruit patients who had mild or moderate COVID-19, which is less common in other studies.

A limitation of our study was the small sample size; the results therefore cannot be generalized to the wider population. Another limitation is the lack of a control group for comparison and selection bias. Most likely, many patients who did not attend a medical consultation after being discharged from the hospital experienced only mild or no prolonged



**Figure.** Flowchart of screening and inclusion of coronavirus disease survivors with long-term symptoms in prospective cohort study, Ribeirão Preto, Brazil.

symptoms at all. The same can be said for healthcare workers who were affected by COVID-19 but did not seek medical consultation. The actual prevalence of long-term symptoms among the reference population is unknown, and our data probably overestimate that prevalence.

In summary, it is likely that a substantial proportion of patients surviving COVID-19 will experience long-term symptoms requiring prolonged care, even after mild to moderate disease. These symptoms might negatively affect patients' quality of life and represent an additional burden for healthcare services and social security.

### Acknowledgments

We thank the outpatient post-COVID-19 team (MINC) that gave us access to patients and offered the space for recruitment of study subjects and data collection; the surviving patients of COVID-19 who contributed to our work; and the research team of the Department of Social Medicine (Public Health) of the Ribeirão Preto Medical School, University of São Paulo (FMRP/USP). We would like to thank Editage (<https://www.editage.com>) for their excellent input on the English language editing.

This work was partially supported by the Fundação de Apoio ao Ensino, Pesquisa e Assistência do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (FAEPA), and National Council for Scientific and Technological Development (CNPq). L.P.B. was granted a scholarship from CNPq to work on Covid-19 research activities (process no. 309098/2020-3).

### About the Author

Dr. Bonifácio is a physiotherapist and current postdoctoral student at the Department of Social Medicine, Ribeirão Preto Medical School, University of São Paulo, Brazil. Her primary areas of interest are primary care, public health and epidemiology, reproductive health, women's and men's health and gender and masculinities, orthopedics, and traumatology.

### References

- Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. *Nat Med*. 2021;27:601-15. <https://doi.org/10.1038/s41591-021-01283-z>
- World Health Organization. Emergency use ICD codes for COVID-19 disease outbreak [cited 2021 May 3]. <https://www.who.int/standards/classifications/classification-of-diseases/emergency-use-icd-codes-for-covid-19-disease-outbreak>
- Havervall S, Rosell A, Phillipson M, Mangsbo SM, Nilsson P, Hober S, et al. Symptoms and functional impairment assessed 8 months after mild COVID-19 among health care workers. *JAMA*. 2021;325:2015-6. <https://doi.org/10.1001/jama.2021.5612>
- Instituto Brasileiro de Geografia e Estatística. Geographic and statistical overview of Ribeirão Preto [in Portuguese] [cited 2021 Mar 29]. <https://cidades.ibge.gov.br/brasil/sp/ribeirao-preto/panorama>
- World Health Organization. Global COVID-19 clinical platform case report form (CRF) for post COVID condition (Post COVID-19 CRF) [cited 2020 Oct 20]. [https://cdn.who.int/media/docs/default-source/3rd-edl-submissions/who\\_crf\\_postcovid\\_feb9\\_2021.pdf](https://cdn.who.int/media/docs/default-source/3rd-edl-submissions/who_crf_postcovid_feb9_2021.pdf)
- Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009;42:377-81. <https://doi.org/10.1016/j.jbi.2008.08.010>
- The WHOQOL Group. Development of the World Health Organization WHOQOL-BREF quality of life assessment. *Psychol Med*. 1998;28:551-8. <https://doi.org/10.1017/S0033291798006667>
- Fleck MP, Louzada S, Xavier M, Chachamovich E, Vieira G, Santos L, et al. Application of the Portuguese version of the abbreviated instrument of quality of life WHOQOL-bref [in Portuguese]. *Rev Saude Publica*. 2000;34:178-83. <https://doi.org/10.1590/S0034-89102000000200012>
- Pedroso B, Pilatti LA, Gutierrez GL, Picinin CT. Calculating WHOQOL-BREF scores and descriptive statistics through Microsoft Excel [in Portuguese]. *Revista Brasileira de Qualidade de Vida*. 2010;2:31-6. <https://doi.org/10.3895/S2175-08582010000100004>
- Centers for Disease Control and Prevention. COVID-19: Long-term effects [cited 2021 May 3]. <https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html>
- Nature. Long COVID: let patients help define long-lasting COVID symptoms [editorial]. *Nature*. 2020;586:170. <https://doi.org/10.1038/d41586-020-02796-2>
- Nehme M, Braillard O, Chappuis F, Courvoisier DS, Guessous I, CoviCare Study Team. Prevalence of symptoms more than seven months after diagnosis of symptomatic COVID-19 in an outpatient setting. *Ann Intern Med*. 2021;174:1252-60. <https://doi.org/10.7326/M21-0878>
- Seeßle J, Waterboer T, Hippchen T, Simon J, Kirchner M, Lim A, et al. Persistent symptoms in adult patients one year after COVID-19: a prospective cohort study. *Clin Infect Dis*. 2021 Jul 5 [Epub ahead of print].
- Antwi-Amoabeng D, Beutler BD, Singh S, Taha M, Ghuman J, Hanfy A, et al. Association between electrocardiographic features and mortality in COVID-19 patients. *Ann Noninvasive Electrocardiol*. 2021;26:e12833. <https://doi.org/10.1111/anec.12833>
- Dixit NM, Churchill A, Nsair A, Hsu JJ. Post-acute COVID-19 Syndrome and the cardiovascular system: what is known? *Am Heart J Plus*. 2021;5:100025.

Address for correspondence: Fernando Bellissimo-Rodrigues or Livia Pimenta Bonifácio, Social Medicine Department, Ribeirão Preto Medical School (USP), Campus Universitário, Monte Alegre 14048-900, Ribeirão Preto, São Paulo, Brazil; email: [fbellissimo@usp.br](mailto:fbellissimo@usp.br) or [livia\\_pb@usp.br](mailto:livia_pb@usp.br)



# Long-Term Symptoms among COVID-19 Survivors in Prospective Cohort Study, Brazil

## Appendix

### Variables of Interest

- Demographic, social, and economic data (age, sex, ethnicity, years of schooling, financial income/person)
  - Body mass index (kg/m<sup>2</sup>)
  - Underlying conditions including chronic heart disease (not hypertension); hypertension; diabetes; chronic lung disease; asthma; tuberculosis; chronic kidney disease; chronic liver disease; chronic neurologic disorder; asplenia; cancer; depression/anxiety; HIV; gastrointestinal disease/gastritis; dyslipidemia; thyroid disease; hearing problem or deficit; vision problem or deficit; stroke; prostatic hyperplasia; transplant; previous surgery; obesity (body mass index >30)
  - Smoking history
  - Hospitalization data
  - Laboratory tests, including hemoglobin, hematocrit, lymphocytes, leukocyte count, platelet count, C-reactive protein, lactate dehydrogenase, aspartate aminotransferase, alanine aminotransferase), D-dimer, urea, and creatinine.
  - Imaging exam: computed tomography

The chest computed tomography findings regarding the degree of severity and impairment of the lungs, such as those identifying viral pneumonia, were evaluated through consensus of 2 radiologists. Severity was evaluated according to the recommendations of the French Society of Thoracic Imaging.

## Abbreviated Version of the WHO Quality of Life Questionnaire (WHOQOL-Bref)

The WHOQOL Group created the WHO Quality of Life Questionnaire (WHOQOL-Bref) to develop a tool with satisfactory psychometric characteristics to assess quality of life in a shorter time (1–3).

This instrument is composed of 26 questions; the first 2 questions comprise a self-assessment of quality of life, while the remaining questions represent the facets of each of the domains evaluated: physical, psychological, social, and environmental relationships. The scores of the domains are calculated by summing the mean scores of “n” questions that make up each domain. The result is multiplied by 4, being represented on a scale from 4 to 20, where a score closer to 20 represents a better and more satisfactory overall quality of life and that of each domain evaluated (1–3).

### References

1. The WHOQOL Group. Development of the World Health Organization WHOQOL-BREF quality of life assessment. *Psychol Med.* 1998;28:551–8. [PubMed](https://pubmed.ncbi.nlm.nih.gov/10111111/)  
<https://doi.org/10.1017/S0033291798006667>
2. Fleck MP, Louzada S, Xavier M, Chachamovich E, Vieira G, Santos L, et al. Application of the Portuguese version of the abbreviated instrument of quality of life WHOQOL-bref [in Portuguese]. *Rev Saude Publica.* 2000;34:178–83. [PubMed](https://pubmed.ncbi.nlm.nih.gov/11590348/) <https://doi.org/10.1590/S0034-8910200000200012>
3. Pedroso B, Pilatti LA, Gutierrez GL, Picinin CT. Calculating WHOQOL-BREF scores and descriptive statistics through Microsoft Excel [in Portuguese]. *Revista Brasileira de Qualidade de Vida.* 2010;2:31–6. <https://doi.org/10.3895/S2175-08582010000100004>

**Appendix Table 1.** World Health Organization classification of severity of the presentation of COVID-19\*

| WHO Clinical Classification | On the basis of available clinical records  | On the basis of self-report, if clinical records are not available   |
|-----------------------------|---|--|
| Mild                        | No hypoxia or pneumonia   | Did not receive oxygen   |
| Moderate                    | Clinical signs of nonsevere pneumonia AND SpO <sub>2</sub> >90% on room air   | Did not receive oxygen   |
| Severe                      | Adults/adolescents: Clinical signs of severe pneumonia AND SpO <sub>2</sub> ≥30 breaths/min; Children: Clinical signs of severe pneumonia AND ≥1 of the following: central cyanosis; OR SpO <sub>2</sub> <90%; OR severe respiratory distress (e.g., fast breathing, grunting, very severe chest indrawing); OR general danger sign(s) (inability to breastfeed or drink, lethargy or unconsciousness, convulsions) | Received oxygen (or said they needed it, but it was not available)   |
| Critical                    | ARDS; OR sepsis/septic shock; OR pulmonary embolism, acute coronary syndrome, acute stroke; OR multi-inflammatory syndrome in children and adolescents temporally related to COVID-19   | Received invasive ventilation (or max available respiratory support) |

\*Taken from World Health Organization Global COVID-19 Clinical Platform Case Report Form for Post COVID condition (Post COVID-19 CRF), [https://cdn.who.int/media/docs/default-source/3rd-edl-submissions/who\\_crf\\_postcovid\\_feb9\\_2021.pdf?sfvrsn=76afd14\\_1&download=true](https://cdn.who.int/media/docs/default-source/3rd-edl-submissions/who_crf_postcovid_feb9_2021.pdf?sfvrsn=76afd14_1&download=true). ARDS, acute respiratory distress syndrome; COVID-19, coronavirus disease; SpO<sub>2</sub>, oxygen saturation; WHO, World Health Organization.

**Appendix Table 2.** Data regarding previous hospital admission among 150 patients surviving the acute phase of COVID-19, Ribeirão Preto, Brazil, 2021

| Hospitalization Data                             | Total, n = 150 |
|--|----------------|
| Ventilatory support/oxygen therapy               |                |
| Yes  | 139 (92.7)     |
| No   | 11 (7.3)       |
| Admitted to the ICU                              | 76 (50.6)      |
| Mechanical ventilation                           |                |
| Yes  | 57 (38.0)      |
| No   | 93 (62.0)      |
| Mean duration of intubation, d (SD)              | 13.5 (±9)      |
| Median   | 10             |
| Need for vasoactive drugs/vasopressors           | 42 (28.0)      |
| Need for hemodialysis                            | 12 (8.0)       |
| Any complication during hospitalization          | 82 (54.6)      |
| Most common complications during hospitalization |                |
| Acute kidney injury                              | 23 (15.3)      |
| Bacterial pneumonia                              | 20 (13.3)      |
| Thromboembolic phenomena                         | 14 (9.3)       |
| Shock  | 12 (8.0)       |
| Cardiac arrhythmia                               | 7 (4.6)        |
| Anemia   | 6 (4.0)        |
| Convulsion                                       | 3 (2.0)        |
| Pericarditis/myocarditis                         | 2 (1.3)        |
| CT exam during hospitalization                   | Total, n = 61  |
| Viral pneumonia on CT                            |                |
| Consistent                                       | 56 (91.8)      |
| Nonsuggestive                                    | 2 (3.3)        |
| Indeterminate                                    | 3 (4.9)        |
| Severity on CT (SIT)                             | Total, n = 59† |
| Absent or minimal (<10%)                         | 3 (5.1)        |
| Moderate (10%–25%)                               | 9 (15.2)       |
| Extensive (25%–50%)                              | 26 (44.1)      |
| Severe (50%–75%)                                 | 21 (35.6)      |
| Critical (>75%)                                  | 0              |

\*Values are no. (%) except as indicated. CT, computed tomography; ICU, intensive care unit; SIT, French Society of Thoracic Imaging.

†In the 2 cases where CT results were considered nonsuggestive of viral pneumonia, the severity was not evaluated.

**Appendix Table 3.** Long-term clinical and laboratory parameters of COVID-19 survivors, Ribeirão Preto, Brazil, 2021\*

| Clinical Parameter                                 | COVID-19 Severity     |                    |                        | p value† | Total, n = 175      |
|--|-----------------------|--------------------|------------------------|----------|---------------------|
|  | Mild/Moderate, n = 35 | Severe, n = 80     | Critical, n = 60       |          |                     |
| Respiratory frequency (n = 174)‡                   |                       |                    |                        |          |                     |
| Mean   | 17.3‡                 | 19.2               | 20                     |          | 19.1                |
| Min–Max  | 12–34                 | 10–32              | 12–32                  |          | 10–34               |
| Median (IQR)                                       | 16.5 (14–18.5)        | 18 (16–22)         | 20 (16–23.75)          | 0.012§   | 18 (16–22)          |
| Oxygen saturation in ambient air, n = 174‡         |                       |                    |                        |          |                     |
| <92%   | 0/35                  | 1/79‡              | 0/60                   |          | 1/174               |
| 92%–94%  | 0/35                  | 5/79               | 2/60                   |          | 7/174               |
| ≥95%   | 35/35                 | 73/79              | 58/60                  |          | 166/174             |
| Median (IQR)                                       | 98 (97–99)            | 98 (96–99)         | 98 (97–99)             | 0.088    | 98 (97–99)          |
| Heart rate, n = 173‡                               |                       |                    |                        |          |                     |
| Mean   | 77.8‡                 | 78.2‡              | 87.7                   |          | 81.4                |
| Min-max  | 50–103                | 50–112             | 53–117                 |          | 50–117              |
| Median (IQR)                                       | 78.5 (69.5–84.5)      | 78 (71–85)         | 87.5 (77.25–98.75)     | >0.001§  | 81 (72–88)          |
| Blood pressure, n = 172‡                           |                       |                    |                        |          |                     |
| SBP≥140 mm Hg                                      | 7/33‡                 | 20/79‡             | 15/60                  |          | 42/172              |
| DBP≥90 mm Hg                                       | 9/33                  | 28/79              | 21/60                  |          | 58/172              |
| SBP≤100 mm H                                       | 5/33                  | 13/79              | 10/60                  |          | 28/172              |
| DBP≤70 mm Hg                                       | 9/33                  | 31/79              | 23/60                  |          | 63/172              |
| Median SBP (IQR)                                   | 120 (110–130)         | 120 (110–140)      | 120 (110–137.5)        | 0.623    | 120 (110–130)       |
| Median DBP (IQR)                                   | 80 (70–90)            | 80 (70–90)         | 80 (70–90)             | 0.943    | 80 (70–90)          |
| Laboratory tests                                   | Mild/Moderate, n = 19 | Severe, n = 56     | Critical, n = 37       | p value† | Total, n = 112      |
| Hemoglobin (ref: 13.9–17.7 g/dL)                   |                       |                    |                        |          |                     |
| Median (IQR)                                       | 13.7 (12.4–14.3)      | 13 (12.2–14.2)     | 12.9 (10.8–13.9)       | 0.396    | 13 (12.1–14.1)      |
| Hematocrit (ref: 39.6%–51.8%)                      |                       |                    |                        |          |                     |
| Median (IQR)                                       | 42 (37–43)            | 40 (37–42)         | 40 (34–43)             | 0.668    | 40 (36–42)          |
| Leukocytes (ref: 3.79–10.33 × 10 <sup>3</sup> /μL) |                       |                    |                        |          |                     |
| Median (IQR)                                       | 6.7 (5–7.8)           | 6.4 (5.2–8.3)      | 7.7 (6.3–9.7)          | 0.065    | 6.8 (5.5–8.6)       |
| Lymphocytes (ref: 1.07–3.12 × 10 <sup>3</sup> /μL) |                       |                    |                        |          |                     |
| Median (IQR)                                       | 1.8 (1.6–2.6)         | 1.7 (1.3–2)        | 2.2 (1.7–2.8)          | 0.001§   | 1.8 (1.4–2.4)       |
| Platelets (ref: 166–389 × 10 <sup>3</sup> /μL)     |                       |                    |                        |          |                     |
| Median (IQR)                                       | 293 (219–337)         | 239 (191–332)      | 291 (233–374)          | 0.113    | 268 (202–341)       |
| C-reactive protein (ref: <1.0 mg/dL)               |                       |                    |                        |          |                     |
| Median (IQR)                                       | 0.4 (0.4–1.6)         | 0.9 (0.4–2.3)      | 1.4 (0.4–2.9)          | 0.128    | 0.9 (0.4–2.3)       |
| LDH (ref: 120–246 U/L)                             |                       |                    |                        |          |                     |
| Median (IQR)                                       | 185.8 (178–237.8)     | 231.35 (204.2–270) | 252.55 (202.25–310.05) | 0.024§   | 236.8 (195.3–289.9) |
| AST (ref: <38.0 U/L)                               |                       |                    |                        |          |                     |
| Median (IQR)                                       | 22 (16–32)            | 24.95 (20–34)      | 23.8 (18.2–29.9)       | 0.219    | 24 (18.5–33)        |
| ALT (ref: 10–49 U/L)                               |                       |                    |                        |          |                     |
| Median (IQR)                                       | 22 (12.5–44.5)        | 40.2 (25–62)       | 27.5 (17.95–48)        | 0.023§   | 35.7 (21–50.1)      |
| D-dimer (ref: ≤0.5 UG/ml)                          |                       |                    |                        |          |                     |
| Median (IQR)                                       | 0.37 (0.31–0.8)       | 0.73 (0.52–0.99)   | 0.92 (0.44–2.54)       | 0.021§   | 0.735 (0.41–1.27)   |
| Urea (ref: 19–49 mg/dL)                            |                       |                    |                        |          |                     |
| Median (IQR)                                       | 30.17 (24.4–37.24)    | 31.88 (25.47–40)   | 32.96 (24.8–40.87)     | 0.696    | 31.78 (25.02–40.76) |
| Creatinine (ref: 0.70–1.30 mg/dL)                  |                       |                    |                        |          |                     |
| Median (IQR)                                       | 0.78 (0.73–0.96)      | 0.87 (0.75–0.97)   | 0.88 (0.74–0.95)       | 0.766    | 0.865 (0.735–0.96)  |

\*ALT, alanine aminotransferase; AST, aspartate aminotransferase; COVID-19, coronavirus disease; DBP, diastolic blood pressure; IQR, interquartile range; LDH, lactate dehydrogenase; SBP, systolic blood pressure.

†P values calculated by using the Kruskal–Wallis test.

‡‡Missing value.

§p<0.05.



**Appendix Table 4.** Results of the WHOQOL questionnaire domains (4–20 pts) in inclusion data of COVID-19 survivors, Ribeirão Preto, Brazil, 2021\*

| Domains                            | Mean  | SD   | Minimum value | Maximum value |
|------------------------------------|-------|------|---------------|---------------|
| Physical domain                    | 12.63 | 1.86 | 7.43          | 17.71         |
| Psychological domain               | 13.89 | 1.94 | 7.33          | 18.00         |
| Social relationships domain        | 15.72 | 2.78 | 4.00          | 20.00         |
| Environment domain                 | 14.42 | 2.17 | 8.50          | 19.50         |
| Self-assessment of quality of life | 14.49 | 2.89 | 4.00          | 20.00         |
| Total                              | 13.97 | 1.65 | 8.62          | 18.15         |

\*COVID-19, coronavirus disease; WHOQOL, World Health Organization Quality of Life.

**Appendix Table 5.** Results of WHOQOL questionnaire self-evaluation inclusion data of COVID-19 survivors, Ribeirão Preto, Brazil, 2021

| Quality of Life Assessment                       | Before COVID-19, n = 175 | After COVID-19, n = 171 |
|--|--------------------------|-------------------------|
| Very poor  | 1 (0.6)                  | 5 (2.9)                 |
| Poor   | 3 (1.7)                  | 6 (3.5)                 |
| Neither poor nor good                            | 29 (16.6)                | 43 (25.2)               |
| Good   | 113 (64.5)               | 96 (56.1)               |
| Very good  | 29 (16.6)                | 21 (12.3)               |
| Satisfaction with your health (in the past 15 d) |                          |                         |
| Very dissatisfied                                |                          | 4 (2.3)                 |
| Dissatisfied                                     |                          | 20 (11.7)               |
| Neither satisfied nor dissatisfied               |                          | 50 (29.3)               |
| Satisfied  |                          | 78 (45.6)               |
| Very satisfied                                   |                          | 19 (11.1)               |

\*Values are no. (%). COVID-19, coronavirus disease; WHOQOL, World Health Organization Quality of Life.